The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...

A device smaller than a quarter is giving heart patients a new lease on life. The Watchman device is implanted in the heart to prevent blood clots from forming without the need of blood thinners. This ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BOSTON — At 3 years, the Amplatzer Amulet device ...